Associated Papers
KEAP1 Mutations Drive Tumorigenesis by Suppressing SOX9 Ubiquitination and Degradation.
Shao N et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2020
33173725 (PubMed )
Supplement: ADVS-7-2001018-s001.pdf
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L et al.
Redox Biology, 2020
32007910 (PubMed )
Supplement: mmc3.xlsx › Table_2_LuAD
MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design.
Cai W et al.
Bmc Genomics, 2018
30075702 (PubMed )
Supplement: 12864_2018_4958_MOESM4_ESM.xlsx › Supplementary_Table_4
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.
Lai Z et al.
Nucleic Acids Research, 2016
27060149 (PubMed )
Supplement: gkw227_Supplementary_Data.zip › nar-03544-met-k-2015-File003.xls › Suppl._Table_3
Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
Khan H et al.
The Biochemical Journal, 2015
Cross-cancer profiling of molecular alterations within the human autophagy interaction network.
Lebovitz CB et al.
Autophagy, 2015
26208877 (PubMed )
Supplement: kaup-11-09-1067362-s001.zip › 1067362_supplemental_files › 2014AUTO0485R1-s03.xlsx › LUAD-mutations
Select a paper to view details